Retatrutide
An experimental triple-hormone peptide that set clinical trial records by reducing average body weight by up to 24.2% in Phase 2.
The Triple-Agonist Architecture: 3 Master Switches
Glucagon-Like Peptide-1 Receptor
Target: Pancreas · Stomach · Hypothalamus (Brain)1. What the natural hormone does
Natural GLP-1 is secreted by L-cells in the lower intestine right after you eat. It signals your body that calories have arrived, slows the stomach from dumping food too quickly, and stimulates the pancreas to produce insulin if blood sugar is elevated.
2. What retatrutide activates
When retatrutide activates the GLP-1 receptor, it dramatically slows stomach emptying (gastric motility) and communicates directly with appetite-control centers in the brain, turning down hunger signals and reducing compulsive 'food noise'.
3. Why it matters in metabolic research
GLP-1 receptor agonism is the clinical foundation of landmark weight-loss medications like semaglutide (Wegovy). It creates dependable, sustained appetite reduction and restores healthy glycemic regulation.
4. Human Clinical Evidence
In the Phase 2 trial published in NEJM (Jastreboff et al., 2023), GLP-1 activation drove sustained early reductions in caloric intake and produced marked improvements in HbA1c in participants with impaired glucose tolerance.
Evidence Gap & Uncertainty: High doses can trigger digestive discomfort, nausea, vomiting, or constipation, especially during rapid dose escalation. Maintaining adequate protein and hydration is critical.
Phase 2 NEJM Clinical Trial: 48-Week Weight Reduction
Jastreboff et al., 2023 (338 adults)Double-blind, randomized, placebo-controlled trial evaluating weekly subcutaneous doses in adults with obesity or overweight without diabetes:
What is Retatrutide?
Retatrutide (code name LY3437943) is an experimental synthetic peptide engineered by Eli Lilly. It is a 'triple agonist', meaning a single molecule designed to bind and turn on three different natural hormone receptors in the human body: GLP-1, GIP, and glucagon.
Why are people interested in it?
People are following retatrutide because its Phase 2 clinical trial showed some of the most substantial average weight reductions ever documented for an investigational medicine — averaging up to 24.2% total body weight reduction over 48 weeks. It is often described in media as a potential successor to semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound).
Primary Research Categories
- Incretin analogues
- Investigational drug substances
How does it work in the body?
Retatrutide works by synchronizing three distinct physiological signaling systems rather than just one. These are three separate hormones, not three variations of GLP:
Receptor-Pathway Mechanism
Triple Agonist Synergy: 3 Distinct Hormonal Pathways
Retatrutide activates three completely different hormone receptors simultaneously. They are distinct endocrine systems, not variations of GLP.
GLP-1 Receptor
Pancreas · Stomach · Hypothalamus
- ▪Slows gastric motility (food empties slower)
- ▪Suppresses appetite & food noise in brain
- ▪Stimulates glucose-dependent insulin
GIP Receptor
Adipose (Fat) Tissue · Pancreas
- ▪Enhances insulin sensitivity in fat cells
- ▪Buffers and reduces GLP-1-mediated nausea
- ▪Synergizes with GLP-1 for central satiety
Glucagon Receptor
Liver · Brown Adipose · Metabolism
- ▪Mobilizes hepatic fat (reduces liver lipid)
- ▪Stimulates thermogenesis & energy burn
- ▪Counters metabolic slowdown during weight loss
Net Metabolic Outcome in Published Trials
Sustained Caloric Deficit (GLP-1 + GIP) + Increased Energy Expenditure (Glucagon) = Up to 24.2% Mean Weight Loss at 48 Weeks
GLP-1 Receptor (Pancreas & Brain)
Slows stomach emptying and signals satiety directly to appetite control centers in the hypothalamus.
GIP Receptor (Pancreas & Adipose Tissue)
Supports insulin sensitivity, regulates lipid storage in fat cells, and helps cushion the nausea often caused by GLP-1.
Glucagon Receptor (Liver & Energy Expenditure)
Signals the liver to mobilize stored fats and stimulates overall caloric burn (thermogenesis) without causing dangerous hypoglycemia.
Key Distinction: Crucially, these are three completely different hormone receptors with distinct physiological jobs. Combining all three is intended to reduce hunger while simultaneously maintaining or boosting energy expenditure.
What has actually been demonstrated in humans?
Retatrutide has been evaluated in a published Phase 2 clinical trial (338 adults) and is completing multiple Phase 3 trials in the global TRIUMPH program (over 2,300 participants). It has demonstrated powerful weight reduction under structured medical supervision, accompanied by predictable incretin-class side effects and a temporary increase in resting heart rate.
NEJM Phase 2 Obesity Trial (Jastreboff et al., 2023)
Duration: 48 weeks · Population: 338 adults with obesity or overweight without diabetesPublished Finding: Mean weight reductions of 8.7% (1 mg), 17.1% (4 mg), 22.8% (8 mg), and 24.2% (12 mg) at 48 weeks compared to 2.1% with placebo.
TRIUMPH-1 Phase 3 Trial (NCT05929066)
Duration: 80 weeks · Population: 2,335 adults with obesity and weight-related health conditionsPublished Finding: Topline disclosures in May 2026 reported up to 28.3% mean weight reduction in the 12 mg arm under the efficacy estimand. Peer-reviewed journal publication pending.
Pharmaceutical Reality vs. Unregulated Research Chemicals
Retatrutide is not approved by the FDA or any global drug regulator. The published evidence reflects the patented, pharmaceutical-grade formulation manufactured by Eli Lilly and administered with medical monitoring. Unregulated powders or liquids sold online as 'retatrutide' are unverified research chemicals with no regulatory oversight, sterile compounding validation, or verified dosing accuracy.
What is still uncertain or unknown?
Long-term cardiovascular outcomes beyond 80 weeks remain unconfirmed until Phase 3 cardiovascular safety trials conclude. The observed resting heart rate elevation (~2–4 bpm peak at 24 weeks) requires ongoing safety monitoring. Has never been clinically evaluated in combination with other peptide compounds.
Clinical Perspectives & Expert Discussions
Explore all perspectivesWhat identifiable clinicians, researchers, and professional bodies have publicly discussed regarding Retatrutide.
Dr. Ania M. Jastreboff, M.D., Ph.D.
Associate Professor of Medicine and Pediatrics, Yale School of Medicine; Director, Yale Obesity Research Center; Board-certified in Internal Medicine, Endocrinology, and Obesity Medicine.
As lead investigator of the published Phase 2 retatrutide trial, Dr. Jastreboff explained that retatrutide's unprecedented 24.2% average weight reduction stems from activating three separate hormone systems simultaneously: GLP-1 and GIP for appetite suppression and insulin sensitivity, combined with glucagon receptor activation to stimulate energy expenditure and reduce liver fat.
Dr. Peter Attia, M.D.
M.D. (Stanford University School of Medicine); former surgical oncology fellow at National Cancer Institute (NIH); author of Outlive: The Science and Art of Longevity; host of The Drive podcast.
Dr. Attia publicly analyzes the metabolic effects of GLP-1 and multi-agonist incretins, cautioning that rapid scale weight loss often includes 25% to 40% skeletal muscle and lean organ mass loss if progressive heavy resistance training and adequate dietary protein (roughly 1 gram per pound of target body weight) are not strictly prioritized.
Dr. Tyna Moore, N.D., D.C.
Licensed Naturopathic Physician (N.D., National University of Natural Medicine) and Chiropractor (D.C., University of Western States) in Oregon; host of The Dr. Tyna Show.
Dr. Moore discusses an alternative clinical approach advocating for conservative starting doses and slower titration schedules than standard pharmaceutical escalation protocols. She argues that starting with lower amounts allows patients to evaluate GI tolerance, manage autonomic nervous system adaptation, and achieve metabolic anti-inflammatory benefits without triggering rapid muscle catabolism.
Dosing Reference
Open Retatrutide Dosing ReferenceAn investigational triple agonist (GIP, GLP-1, and glucagon receptors) in Phase 3 clinical development. There is no FDA-approved formulation, no approved prescribing label exists, and research chemicals sold online are unverified for purity or sterility.
Therapept separates official product labels, published clinical study interventions, animal research, clinical references, and community-reported ranges — never blended into one number.
Research at a Glance
Open the full evidence file (2 records)2 records in this file
- CLINICAL TRIAL2
Publication span: 2023–2026
What Has Actually Been Studied
- Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH-1 topline) (Company news release, 2026) — Sponsor Phase 3 topline disclosure.
- Triple-hormone-receptor agonist retatrutide for obesity — a Phase 2 trial (New England Journal of Medicine, 2023) — Randomised, double-blind, placebo-controlled Phase 2 trial.
What is Still Unknown
What we know
- Jastreboff et al. 2023 (NEJM) is a published Phase 2 obesity trial of investigational retatrutide.
- Lilly has issued Phase 3 TRIUMPH-1 topline disclosures. Those are sponsor communications, not a peer-reviewed paper and not an approval.
- No Drugs@FDA approved product as of this review. Not interchangeable with semaglutide or tirzepatide.
Editorial reading of the records below, labelled as Therapept analysis. How records are built
What remains uncertain
- The full peer-reviewed TRIUMPH clinical package, including estimands and adverse-event tables.
- Whether, and when, FDA will license a product — a Phase 3 topline is not a listing decision.
Preparation and Handling
Lyophilized peptides ship as freeze-dried powders; whatever happens next involves diluents, concentrations and storage conditions that are compound- and product-specific.
United States Regulatory Status
Investigational
- No approved United States product in Drugs@FDA as of this review.
- CAS 2381089-83-2 is the identifier used in DrugBank and related registries.
- A Phase 2 obesity trial is published in NEJM (2023). Sponsor Phase 3 topline disclosures in the TRIUMPH programme are not a listing decision and are not an approved label.
- Not interchangeable with semaglutide or tirzepatide, which have different receptor profiles and approved products.
Technical Chemical SpecificationsClick to view CAS, sequence, and molecular formulas
- Molecular weight
- 4731.33 g/mol (average mass, widely cited for the free base)
- Sequence length
- Not recorded
- CAS number
- 2381089-83-2
- PubChem CID
- None assigned
- Compound class
- Investigational triple agonist of GIP, GLP-1 and glucagon receptors
- Sequence
- Unknown / Unassigned
- Molecular formula
- Unknown
- Molecular weight
- 4731.33 g/mol (average mass, widely cited for the free base)
- CAS number
- 2381089-83-2
- PubChem CID
- Unknown
Sources
Last reviewed 12 September 2026 · Compiled by Therapept Editorial · How these records are built